<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3116">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04362059</url>
  </required_header>
  <id_info>
    <org_study_id>RHM CRI0399</org_study_id>
    <nct_id>NCT04362059</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19</brief_title>
  <acronym>COVSurf</acronym>
  <official_title>A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Southampton NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung surfactant is present in the lungs. It covers the alveolar surface where it reduces the
      work of breathing and prevents the lungs from collapsing. In some respiratory diseases and in
      patients that require ventilation this substance does not function normally. This study will
      introduce surfactant to the patients lungs via the COVSurf Drug Delivery System
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis behind the proposed trial of surfactant therapy for COVID-19 infected patients
      requiring ventilator support is that endogenous surfactant is dysfunctional. This could be
      due to decreased concentration of surfactant phospholipid and protein, altered surfactant
      phospholipid composition, surfactant protein proteolysis and/or oedema protein inhibition of
      surfactant surface tension function and/or oxidative inactivation of surfactant proteins.
      Variations of these dysfunctional mechanisms have been reported in a range of lung diseases,
      including cystic fibrosis and severe asthma, and in child and adult patients with ARDS. Our
      studies of surfactant metabolism in adult ARDS patients showed altered percentage composition
      of surfactant PC, with decreased DPPC and increased surface tension-inactive unsaturated
      species, and decreased concentrations of both total PC and phosphatidylglycerol (PG)

      The SARS-CoV-2 virus binds to the angiotensin converting enzyme-2 (ACE2) receptor, which is
      preferentially expressed in the peripheral lung ATII cells. Consequent viral infection of
      ATII cells could reduce cell number and impair the capacity of the lungs to synthesise and
      secrete surfactant. This, however, has not yet been demonstrated empirically in COVID-19
      patients. If this is the case, then exogenous surfactant administration to the lungs is
      potential one treatment option to mitigate disease severity in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Anticipated">November 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 27, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygenation Improvement</measure>
    <time_frame>3 months</time_frame>
    <description>To assess the improvement in oxygenation as determined by the PaO2/FiO2 ratio after treatment with study treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary ventilation Improvement</measure>
    <time_frame>3 months</time_frame>
    <description>To assess the improvement in pulmonary ventilation as determined by the Ventilation Index (VI), where VI = [RR x (PIP - PEEP) × PaCO2]/1000 after study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment of Frequency and Severity of Adverse Events</measure>
    <time_frame>3 months</time_frame>
    <description>To assess safety as judged by the frequency and severity of adverse events and severe adverse events (SAEs).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Respiratory Infections</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be administered surfactant via COVSurf Drug Delivery System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients shall receive regular Standard of Care treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>COVSurf Drug Delivery System</intervention_name>
    <description>Device introduces surfactant to the patients lungs</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of care treatment for respiratory illness</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years old

          -  Confirmed COVID-19 positive by PCR

          -  Within 24 hours of mechanical ventilation

          -  Assent or professional assent obtained

        Exclusion Criteria:

          -  Imminent expected death within 24 hours

          -  Specific contraindications to surfactant administration (e.g. known allergy,
             pneumothorax, pulmonary haemorrhage)

          -  Known or suspected pregnancy

          -  Stage 4 severe chronic kidney disease or requiring dialysis (i.e., eGFR &lt; 30)

          -  Liver failure

          -  Anticipated transfer to another hospital, which is not a study site within 72 hours.

          -  Current participation or participation in another study within the last month that in
             the opinion of the investigator would prevent enrollment for safety purposes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P Grocott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Southampton NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danny B Pratt</last_name>
    <phone>02381204989</phone>
    <phone_ext>3943</phone_ext>
    <email>danny.pratt@uhs.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Pratt</last_name>
      <phone>02381204989</phone>
      <email>danny.pratt@uhs.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ahilanandan Dushianthan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subarna Roy</last_name>
      <email>subarna.roy@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Howard Clark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200301-sitrep-41-covid-19.pdf?sfvrsn=6768306d_2</url>
    <description>WHO Master Protocol 2020</description>
  </link>
  <results_reference>
    <citation>Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventós AA, Lemaire F, Long W, Zaccardelli DS, Pattishall EN. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med. 1996 May 30;334(22):1417-21.</citation>
    <PMID>8618579</PMID>
  </results_reference>
  <results_reference>
    <citation>Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Collaborative European Multicenter Study Group. Pediatrics. 1988 Nov;82(5):683-91.</citation>
    <PMID>2903480</PMID>
  </results_reference>
  <results_reference>
    <citation>Dushianthan A, Goss V, Cusack R, Grocott MP, Postle AD. Altered molecular specificity of surfactant phosphatidycholine synthesis in patients with acute respiratory distress syndrome. Respir Res. 2014 Nov 7;15:128. doi: 10.1186/s12931-014-0128-8.</citation>
    <PMID>25378080</PMID>
  </results_reference>
  <results_reference>
    <citation>Goss V, Hunt AN, Postle AD. Regulation of lung surfactant phospholipid synthesis and metabolism. Biochim Biophys Acta. 2013 Feb;1831(2):448-58. doi: 10.1016/j.bbalip.2012.11.009. Epub 2012 Nov 27. Review.</citation>
    <PMID>23200861</PMID>
  </results_reference>
  <results_reference>
    <citation>Günther A, Schmidt R, Harodt J, Schmehl T, Walmrath D, Ruppert C, Grimminger F, Seeger W. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J. 2002 May;19(5):797-804.</citation>
    <PMID>12030716</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.</citation>
    <PMID>32142651</PMID>
  </results_reference>
  <results_reference>
    <citation>Möller JC, Schaible T, Roll C, Schiffmann JH, Bindl L, Schrod L, Reiss I, Kohl M, Demirakca S, Hentschel R, Paul T, Vierzig A, Groneck P, von Seefeld H, Schumacher H, Gortner L; Surfactant ARDS Study Group. Treatment with bovine surfactant in severe acute respiratory distress syndrome in children: a randomized multicenter study. Intensive Care Med. 2003 Mar;29(3):437-46. Epub 2003 Feb 15.</citation>
    <PMID>12589529</PMID>
  </results_reference>
  <results_reference>
    <citation>Postle AD, Mander A, Reid KB, Wang JY, Wright SM, Moustaki M, Warner JO. Deficient hydrophilic lung surfactant proteins A and D with normal surfactant phospholipid molecular species in cystic fibrosis. Am J Respir Cell Mol Biol. 1999 Jan;20(1):90-8.</citation>
    <PMID>9870921</PMID>
  </results_reference>
  <results_reference>
    <citation>Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. 2020 May 21;526(1):135-140. doi: 10.1016/j.bbrc.2020.03.044. Epub 2020 Mar 19.</citation>
    <PMID>32199615</PMID>
  </results_reference>
  <results_reference>
    <citation>Rebello CM, Jobe AH, Eisele JW, Ikegami M. Alveolar and tissue surfactant pool sizes in humans. Am J Respir Crit Care Med. 1996 Sep;154(3 Pt 1):625-8.</citation>
    <PMID>8810596</PMID>
  </results_reference>
  <results_reference>
    <citation>Rodríguez-Capote K, Manzanares D, Haines T, Possmayer F. Reactive oxygen species inactivation of surfactant involves structural and functional alterations to surfactant proteins SP-B and SP-C. Biophys J. 2006 Apr 15;90(8):2808-21. Epub 2006 Jan 27.</citation>
    <PMID>16443649</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmidt R, Markart P, Ruppert C, Wygrecka M, Kuchenbuch T, Walmrath D, Seeger W, Guenther A. Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration. Respir Res. 2007 Jul 27;8:55.</citation>
    <PMID>17662121</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwarz KB. Oxidative stress during viral infection: a review. Free Radic Biol Med. 1996;21(5):641-9. Review.</citation>
    <PMID>8891667</PMID>
  </results_reference>
  <results_reference>
    <citation>Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr;20(4):425-434. doi: 10.1016/S1473-3099(20)30086-4. Epub 2020 Feb 24.</citation>
    <PMID>32105637</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

